معرفی
Emily Cheng is a Professor at Weill Cornell Medical College and a Member at Memorial Sloan Kettering Cancer Center (MSKCC), where she leads the Cheng Lab focused on molecular mechanisms of cell death and their implications in cancer. Her work bridges basic science and translational research in oncology, immunology, and cell signaling.
Her research centers on understanding apoptosis, immunogenic cell death, and epigenetic regulation in tumorigenesis. Using techniques such as quantitative proteomics, genome-wide screens, single-cell omics, and mouse models, her lab investigates how dysregulation of BCL-2 family proteins and epigenetic modifiers like SETD2 contribute to cancer progression and therapy resistance. A major focus is on enhancing anti-tumor immunity through targeted induction of immunogenic cell death.
The selected publications reflect a strong trajectory in elucidating core apoptotic pathways, modeling BCL-2 family interactions, overcoming drug resistance in lung cancer, and uncovering epigenetic vulnerabilities in kidney cancer. Her work has significant implications for developing precision cancer therapies, particularly involving BH3-mimetics and combination immunotherapies.
- NCI Howard Temin Award (2003)
- Searle Scholar Award (2005)
- ACS Research Scholar Award (2010)
Dr. Cheng mentors students and researchers in the Graduate School of Medical Sciences and is affiliated with the Cell & Developmental Biology program. Her lab receives support from major cancer research institutions and contributes to advancing mechanism-based anti-cancer therapies. She has trained extensively in pathology and molecular sciences, contributing both clinically and scientifically to oncology.
The Cheng Lab actively investigates survival/death signaling, epigenetic tumor suppressors, and strategies to enhance immunotherapy through cell death modulation. It collaborates across disciplines to translate molecular findings into therapeutic innovations.
حوزههای پژوهشی
